

# Patients for patients – qualified peer-counselling and self-management for patients with rare chronic diseases

|  |   |   |
|--|---|---|
| <b>Submission date</b><br>27/09/2017   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol            |
| <b>Registration date</b><br>20/10/2017 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan<br><input checked="" type="checkbox"/> Results |
| <b>Last Edited</b><br>05/07/2021       | <b>Condition category</b><br>Genetic Diseases     | <input type="checkbox"/> Individual participant data  |

## Plain English summary of protocol

### Background and study aims

The aim of this study is to assess a brief, peer-delivered self-management intervention for patients with rare chronic diseases. Patients affected by four rare diseases are included in the study: neurofibromatosis type 1 (a genetic condition where tumours grow along the nerves), Marfan syndrome (a disorder of the body's connective tissues), primary sclerosing cholangitis (a chronic liver disease) and pulmonary arterial hypertension (high blood pressure in the arteries that go from the heart to the lungs).

### Who can participate?

Patients aged over 16 with either neurofibromatosis type 1, Marfan syndrome, primary sclerosing cholangitis, or pulmonary arterial hypertension

### What does the study involve?

Participants are randomly allocated to either an intervention group or a control group. The control group receives care as usual during the study and receives the intervention after the study has ended. The intervention group receives an intervention comprised of two components: a self-management manual and peer-counselling. For 6 weeks, participants complete the self-management manual at home. The first session includes a disease-specific information module. The manual follows an approach based on Acceptance and Commitment Therapy (ACT). ACT supports acceptance of negative conditions, feelings and thoughts rather than fighting against them and targets the question on how to live in line with one's values. While working on the manual, participants are supported by weekly telephone conversations (max. 30 minutes) with a peer-counsellor who also has one of the four rare diseases named above. Participants' acceptance of their illness is assessed before, directly after and 6 months after the intervention has ended.

### What are the possible benefits and risks of participating?

Participating in the intervention may lead to improved disease management 6 months later compared to care as usual.

Where is the study run from?  
University Medical Center Hamburg-Eppendorf (Germany)

When is the study starting and how long is it expected to run for?  
November 2014 to October 2018

Who is funding the study?  
Robert Bosch Foundation (Germany)

Who is the main contact?  
1. Prof. Bernd Löwe  
2. Dr Miriam Depping

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Bernd Löwe

**Contact details**  
University Medical Center Hamburg- Eppendorf | UKE  
Institute and Outpatients Clinic for Psychosomatic Medicine and Psychotherapy  
Building O25  
Martinistr 52  
Hamburg  
Germany  
20246

**Type(s)**  
Scientific

**Contact name**  
Dr Miriam Katharina Depping

**Contact details**  
University Medical Center Hamburg- Eppendorf | UKE  
Institute and Outpatients Clinic for Psychosomatic Medicine and Psychotherapy  
Building W37  
Martinistr 52  
Hamburg  
Germany  
20246

## Additional identifiers

EudraCT/CTIS number

IRAS number

**ClinicalTrials.gov number**

**Secondary identifying numbers**

Patients for patients RCT

## **Study information**

### **Scientific Title**

Patients for patients – qualified peer-counselling and self-management for patients with rare chronic diseases

### **Study objectives**

Primary hypothesis of the study is that participating in the intervention (consisting of self-management and peer-counselling) leads to a significantly stronger improvement in coping with the disease (indexed by acceptance) after the intervention compared to care as usual.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics Committee of the Hamburg Medical Council, 03/08/2017, ref: PV5088

### **Study design**

Single-center unmasked randomized controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Home

### **Study type(s)**

Quality of life

### **Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Neurofibromatosis type 1, Marfan Syndrome, primary sclerosing cholangitis (PSC), pulmonary arterial hypertension (PAH)

### **Interventions**

Study coordination is single centered, participants receive their Intervention at home and by phone and will be recruited from all over Germany. Participants are randomly assigned to either condition after providing informed consent. Unmasked random assignment to intervention or waiting-control group.

The 6-week intervention combines self-management and peer-counselling. Participants receive a self-management manual including 6 modules on the following topics: Disease-specific information, dealing with negative emotions, accepting negative thoughts and emotions, values and value-based goals. The information module is the only disease-specific module. All other chapters are generic and do not address a specific condition. Additionally to the manual, participants receive weekly telephone support by a peer counsellor (max. 30 minutes). During the phone calls the recipients of the questions are asked whether working on the current chapter worked and which difficulties arose. The recipients have the opportunity to ask questions regarding the content and process. Peer-counsellors are trained before the intervention starts. They further receive supervision provided by a medical psychotherapist in order to be sufficiently supported during their work. Peer-counsellors further receive consulting guidelines.

The control group receives care as usual during the study. As a waiting control group participants receive the intervention after the trial has ended.

Data assessment will take place before, directly after as well as six months after the intervention has ended. Assessed variables include patient global impression of change, coping mechanisms, quality of life, illness-perception, illness-related fears and illness-related cognitions, psychopathology, social support and optimism. Further, acceptance and subjective usefulness of the intervention will be assessed after the intervention.

## **Intervention Type**

Other

## **Primary outcome measure**

Subscale "Acceptance" of the Illness Cognition Questionnaire (ICQ; Evers, Kraaimaat et al. 2001). The instrument assesses ways of cognitively evaluating the aversive character of a chronic illness on the scales helplessness, acceptance, and perceived benefits. Timepoints: pre-assessment (before the intervention), post-assessment (directly after the intervention) and follow-up assessment (6 months after the intervention)

## **Secondary outcome measures**

1. Patient's belief about the efficacy of treatment, assessed using Patient Global Impression of Change (PGIC) at post and follow-up assessment
2. Coping mechanisms, assessed using the Health Education Impact Questionnaire (HeiQ; Schuler, Musekamp et al., 2013) at pre, post and follow-up assessment
3. Illness perceptions, assessed using the Illness Perception Questionnaire (IPQ-R; Glattacker, Bengel et al., 2009) at pre, post and follow-up assessment
4. Health-related quality of life, assessed using the 12-Item Short-Form Health Survey (SF-12; Ware, Kosinski et al., 1996) at pre, post and follow-up assessment
5. Presence and severity of symptoms of depression, assessed using the Patient Health Questionnaire 9-item depression scale (PHQ-9; Kroenke, Spitzer et al., 2001) at pre, post and follow-up assessment
6. Somatic symptom severity, assessed using Patient Health Questionnaire 15-item somatic scale (PHQ-15; Kroenke, Spitzer et al., 2002) at pre, post and follow-up assessment
7. The presence and severity of anxiety symptoms, assessed using the Patient Health Questionnaire 7-item anxiety scale (GAD-7; Löwe, Decker et al., 2008) at pre, post and follow-up assessment

8. Perceived social support, assessed using Social Support Questionnaire – Fragebogen zur sozialen Unterstützung (F-Sozu; Fydrich, Sommer et al., 2009) at pre, post and follow-up assessment

Other measures:

1. Client Sociodemographic and Service Receipt Inventory (CSSRI) – adapted version, used at pre assessment
2. Acceptance and perceived usefulness of the intervention and the specific modules, assessed using self-generated measure at post assessment
3. The perceived relationship with the peer consultant, assessed using self-generated measure at post assessment
4. Subjectively perceived goal achievement, assessed using self-generated measure at post assessment
5. The perceived quality of the peer-counselling sessions from the perspective of the peer-counsellor, assessed using self-generated measure at post assessment
6. Whether expectations of peer-counsellors regarding the intervention have been met, assessed using self-generated measure at post assessment
7. Sociodemographic variables, assessed at pre assessment
8. Helplessness and perceived benefits, assessed using the Illness Cognition Questionnaire (ICQ; Evers, Kraaimaat et al. 2001) at pre, post and follow-up assessment
9. Fear of the progression of the illness and future worries concerning the illness, assessed using Fear of Progression Questionnaire - Short-Form (PA-F-KF; Mehnert, Herschbach et al, 2006) at pre, post and follow-up assessment
10. Optimism and pessimism, assessed using LOT-R (Glaesmer, Hoyer et al., 2008) at pre, post and follow-up assessment
11. General self-efficacy, assessed using Self-efficacy Scale – Allgemeine Selbstwirksamkeitserwartung (SWE; Jerusalem & Schwarzer, 1999) at pre, post and follow-up assessment

**Overall study start date**

10/11/2014

**Completion date**

31/10/2018

## **Eligibility**

**Key inclusion criteria**

1. Diagnosis of one of four specific rare chronic conditions (Neurofibromatosis type 1, Marfan syndrome, primary sclerosing cholangitis, pulmonary arterial hypertension) given by a clinician
2. Limited functionality caused by the disease
3. Minimum age of 16 years
4. Willingness to participate in all parts of the intervention including the self-management manual, the peer counselling as well as willingness to answer to questionnaires
5. Sufficient German language skills

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

128

**Total final enrolment**

89

**Key exclusion criteria**

1. Life threatening state of health
2. Acute mental or physical burden requiring an immediate treatment
3. Acute suicidality
4. Current psychotherapeutic, psychosomatic or psychiatric treatment
5. Severe cognitive, auditory or visual impairment
6. Inability to answer study questionnaires

**Date of first enrolment**

05/10/2017

**Date of final enrolment**

28/02/2018

**Locations****Countries of recruitment**

Germany

**Study participating centre**

**Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf**

University Medical Center Hamburg- Eppendorf | UKE

Institute and Outpatients Clinic for Psychosomatic Medicine and Psychotherapy

Building O25

Martinistr 52

Hamburg

Germany

20246

**Sponsor information****Organisation**

University Medical Center Hamburg- Eppendorf | UKE

**Sponsor details**

Martinistr 52  
Hamburg  
Germany  
20246

**Sponsor type**

University/education

**ROR**

<https://ror.org/01zgy1s35>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Robert Bosch Stiftung

**Alternative Name(s)**

Robert Bosch Foundation, Robert Bosch Stiftung GmbH, RBS

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

Germany

## **Results and Publications**

**Publication and dissemination plan**

A study protocol is currently being prepared for submission to be published. Planned publication in a high-impact peer reviewed journal.

**Intention to publish date**

31/10/2019

**Individual participant data (IPD) sharing plan**

The data sharing plans for the current study are unknown and will be made available at a later date.

**IPD sharing plan summary**

Data sharing statement to be made available at a later date

## Study outputs

| Output type                        | Details                  | Date created | Date added | Peer reviewed? | Patient-facing? |
|------------------------------------|--------------------------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a>    | results                  | 24/02/2021   | 25/02/2021 | Yes            | No              |
| <a href="#">Other publications</a> | intervention development | 02/07/2021   | 05/07/2021 | Yes            | No              |